ERK and p38 MAPK activities determine sensitivity to PI3K/mTOR inhibition via regulation of MYC and YAP

Aberrant activation of the PI3K/mTOR-pathway is a common feature of many cancers and an attractive target for therapy, but resistance inevitably evolves is as the case for any cancer cell targeted therapy. In animal tumor models, chronic inhibition of PI3K/mTOR initially inhibits tumor growth, but o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Res
Glavni autori: Muranen, Taru, Selfors, Laura M., Hwang, Julie, Gallegos, Lisa L., Coloff, Jonathan L., Thoreen, Carson C., Kang, Seong A., Sabatini, David M., Mills, Gordon B., Brugge, Joan S.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161652/
https://ncbi.nlm.nih.gov/pubmed/27913436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0155
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items